Journal
BLOOD
Volume 104, Issue 12, Pages 3635-3641Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-04-1358
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-30616] Funding Source: Medline
Ask authors/readers for more resources
We have shown previously that fibrin(ogen) binding potentiates the capacity of fibroblast growth factor 2 (FGF-2) to stimulate endothelial cell (EC) proliferation. We have now investigated the receptor requirement for EC proliferation by fibrinogen-bound FGF-2. ECs were cultured with 25 ng/mL FGF-2 with or without 10 mug/mL fibrinogen, and proliferation was measured as H-3-thymidine incorporation. Proliferation was increased 2.4 +/- 0.5-fold over medium alone with FGF-2 and increased significantly more to 4.0 +/- 0.7-fold with fibrinogen and FGF-2 (P < .005). Addition of 7E3 or LM609, antibodies to alpha(nu)beta(3), inhibited EC proliferation with fibrinogen-bound FGF-2 by 80% +/- 8% (P < .001) or 67% +/- 14% (P < .002), respectively, to levels significantly less than that observed with FGF-2 alone (P < .001). Neither LM609 nor 7E3 exhibited any inhibition of activity with FGF-2 alone. Peptide GRGDS caused dose-dependent inhibition of proliferation by fibrinogen-bound FGF-2 of 31% +/- 8%, 45% +/- 9%, and 68% +/- 11% at 0.25, 0.5, and 1 mM, respectively. Coimmunoprecipitation and immunofluorescence studies demonstrated a direct specific association between alpha(nu)beta(3) and FGF receptor 1 (FGFR1) in ECs and fibroblasts when exposed to both FGF-2 and fibrinogen but not with vitronectin. We conclude that fibrinogen binding of FGF-2 enhances EC proliferation through the coordinated effects of colocalized alpha(nu)beta(3) and FGFR1. (C) 2004 by The American Society of Hematology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available